Payment overview · 2025
General Payments
$702.38
28 reported records · 15 companies
Healthcare provider profile · identity verified
Cortney Jones
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · WHITEVILLE, NC · NPI 1902228240
Verified facts
What the public records show
CMS Open Payments records show Cortney Jones received $702.38 in general payments during 2025 across 28 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $258.92 | 36.9% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.53 | 11.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.56 | 8.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $53.88 | 7.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.95 | 4.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.22 | 4.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.92 | 4.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.74 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.60 | 3.2% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.96 | 3.0% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.27 | 2.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.07 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.74 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.01 | 2.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.01 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $702.38 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $216.50 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $100.93 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.53 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.51 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $56.56 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53.88 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.22 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.92 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 181 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
181 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 462 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 82 |
| Gabapentin | Gabapentin | 313 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 223 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 45 |
| Omeprazole | Omeprazole | 203 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 51 |
| Farxiga | Dapagliflozin Propanediol | 181 | 40 |
| Lisinopril | Lisinopril | 181 | 43 |
| Potassium Chloride | Potassium Chloride | 176 | 40 |
| Furosemide | Furosemide | 170 | 49 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 47 |
| Tramadol Hcl | Tramadol Hcl | 160 | 40 |
| Metformin Hcl | Metformin Hcl | 156 | 41 |
| Allopurinol | Allopurinol | 152 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 152 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 36 |
| Trazodone Hcl | Trazodone Hcl | 148 | 28 |
| Losartan Potassium | Losartan Potassium | 123 | 29 |
| Ozempic | Semaglutide | 121 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 32 |
| Sertraline Hcl | Sertraline Hcl | 91 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 22 |
| Famotidine | Famotidine | 87 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 20 |
| Jardiance | Empagliflozin | 83 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 18 |
| Ezetimibe | Ezetimibe | 79 | 27 |
| Meloxicam | Meloxicam | 75 | 21 |
| Pregabalin | Pregabalin | 75 | 14 |
| Glipizide Er | Glipizide | 74 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 67 | 17 |
| Lovastatin | Lovastatin | 67 | 18 |
| Carvedilol | Carvedilol | 66 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 66 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 62 | 13 |
| Mounjaro | Tirzepatide | 60 | 11 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Nifedipine Er | Nifedipine | 56 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 18 |
| Valsartan | Valsartan | 56 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 54 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 11 |
| Prednisone | Prednisone | 53 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 12 |
| Spironolactone | Spironolactone | 52 | 18 |
| Linzess | Linaclotide | 51 | 13 |
| Simvastatin | Simvastatin | 50 | 14 |
| Celecoxib | Celecoxib | 49 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 40 |
| Bupropion Xl | Bupropion Hcl | 48 | 12 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 15 |
| Trulicity | Dulaglutide | 46 | 11 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Bumetanide | Bumetanide | 45 | 11 |
| Ibuprofen | Ibuprofen | 45 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 12 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 11 |
| Ondansetron Odt | Ondansetron | 41 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Eliquis | Apixaban | 38 | suppressed |
| Fluconazole | Fluconazole | 38 | 20 |
| Glipizide | Glipizide | 36 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Nystatin | Nystatin | 32 | 15 |
| Atenolol | Atenolol | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Cilostazol | Cilostazol | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | 11 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $702.38 · 28 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, GVOKE HYPOPEN, IBSRELA, Kerendia, Korlym, MOUNJARO, Ozempic, PURIFIED CORTROPHIN GEL, REPATHA, Rybelsus, TRELEGY ELLIPTA, VAXELIS, VAXNEUVANCE, VRAYLAR, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error